ABSTRACT
OBJECTIVE: To investigate the association between pre-treatment thrombocytosis and prognosis in patients with ovarian cancer (OC). METHODS: PubMed, EMBASE, and the Cochrane Library were searched for articles regarding the prognosis of OC patients with pre-treatment thrombocytosis by the end of March 2018. Pooled estimates for overall survival (OS) and progression-free survival (PFS) events were calculated as hazard ratios (HRs) either on a fixed or random effect model by Stata 13.0 software. Funnel plot and Egger's test were applied to evaluate publication bias and sensitivity analyses were undertaken to estimate the strength of outcomes. RESULTS: Eleven studies that met the inclusion criteria were enrolled, including a total of 4,953 patients. Pooled results showed that pre-treatment thrombocytosis was significantly associated with OS (HR=1.722; 95% confidence interval [CI]=1.437–2.064) and PFS (HR=1.452; 95% CI=1.323–1.593) in the cohort. Significant correlation was found in OS and PFS between pre-treatment thrombocytosis and both epithelial OC (all stages and differentiation degrees of OC) and advanced epithelial OC (III or IV) by subgroup analyses, which were performed according to publication year, country, case numbers, OC category, International Federation of Gynecology and Obstetrics stage, and cut-off value. However, subgroup analyses indicated no significant correlation between pre-treatment thrombocytosis and OS for patients with high-grade serous (poorly differentiated or undifferentiated) OC (HR=1.220; 95% CI=0.946–1.573; p=0.125). Egger's test demonstrated no obvious publication bias in the articles enrolled in this study (OS: p=0.226; PFS: p=0.071). CONCLUSION: Pre-treatment thrombocytosis might be taken as an independent prognostic indicator for patients with OC.
Subject(s)
Humans , Cohort Studies , Disease-Free Survival , Gynecology , Obstetrics , Ovarian Neoplasms , Prognosis , Publication Bias , Publications , ThrombocytosisABSTRACT
[Objective] To explore the clinical effects of three methods in the treatment of cesarean scar pregnancy.[Method]All the patients with cesarean scar pregnancy accepted treatment at 2 affiliated hospitals of Sun Yat-Sen University from May 2006 to September 2016 were retrospectively analyzed.According to their different therapies,186 of them were divided into three groups:surgery group (undergone transvaginal removal of ectopic pregnancy tissue and repair of uterine defect,73 cases),medical treatment group (treated with medical and combined with curettage,51 cases),UAE group (treated with UAE and combined with suction curettage,62 cases).The success rate,hospitalization time,hospitalization expenses and treatment side effects of the three groups were compared.[Result] The success rates of the three groups were 98.6％,54.9％,and 80.6％;The hospitalization days of the three groups were (7.3 ± 3.3) days,(16.2 ± 11.2) days,(12.6 ± 10.4) d.The hospitalization expenses of the three groups were (7 967 ±1 987) yuan,(5 499-± 1 965) yuan,(15 863 ± 5 941) yuan.The treatment side effects of the three groups were 15.1％,23.5％,and 37.1％.The success rate,hospitalization days,hospitalization expenses and treatment side effects of the three groups were statistically different (P ＜ 0.05).The surgery group has a highest success rate,shortest hospitalization time,lower hospitalization expenses,and less complication.[Conclusions] Transvaginal removal of ectopic pregnancy tissue and repair of uterine defect is a reliable treatment for CSP.